InvestSMART

Immutep Limited (ASX: IMM) - Share Price

Current share price for IMM : $0.053 0.002 (3.64%)+

Immutep Ltd (IMM), an ASX-listed company, is a Phase III, clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG 3) related immunotherapies for cancer and autoimmune disease.

IMM General Information +

ASX Code IMM
Website http://www.immutep.com
Industry/Sector Biotechnology
Market Cap ($M) 78
IMM Share Price $0.053
Day High $0.055
Day Low $0.052
Last Close $0.055
IMM Share Price Movement $0.00 ( 3.64% )
Prices as at 16:40, 8 Jul 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Immutep Limited (IMM) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Immutep Limited (IMM) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Immutep Limited (IMM) price-sensitive announcements

IMM - Immutep Quarterly Activities Report and Appendix 4C
Immutep Limited reported its quarterly activities for the period ending 31 March 2026. The
Immutep Limited (IMM)
30 Apr 2026 | 9:01 AM
IMM - Immutep receives FDA ODD for Efti in Soft Tissue Sarcoma
Immutep Limited has announced that the FDA has granted Orphan Drug Designation (ODD) for e
Immutep Limited (IMM)
15 Apr 2026 | 9:27 AM
IMM - Update on Phase I Study of IMP761 for Autoimmune Diseases
Immutep Limited has announced a positive update on its Phase I study of IMP761, a first-in
Immutep Limited (IMM)
19 Mar 2026 | 8:20 AM
IMM - Reinstatement to Quotation
On March 13, 2026, ASX Compliance announced the immediate lifting of the suspension of tra
Immutep Limited (IMM)
13 Mar 2026 | 8:57 AM

Immutep Limited (IMM) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
Immutep Limited (IMM)
ORDINARY FULLY PAID
 Health Care $78 Ceasing to be a substantial holder 1 Jul 2026 8:14AM $0.053 $0.053 fallen by 0%
Immutep Limited (IMM)
ORDINARY FULLY PAID
 Health Care $78 Becoming a substantial holder 17 Jun 2026 8:22AM $0.046 $0.053 risen by 15.22%
Immutep Limited (IMM)
ORDINARY FULLY PAID
 Health Care $78 Ceasing to be a substantial holder 16 Jun 2026 8:16AM $0.048 $0.053 risen by 10.42%
Immutep Limited (IMM)
ORDINARY FULLY PAID
 Health Care $78 Becoming a substantial holder 15 Jun 2026 8:19AM $0.047 $0.053 risen by 12.77%
Immutep Limited (IMM)
ORDINARY FULLY PAID
 Health Care $78 Ceasing to be a substantial holder 10 Jun 2026 8:19AM $0.047 $0.053 risen by 12.77%
Immutep Limited (IMM)
ORDINARY FULLY PAID
 Health Care $78 Ceasing to be a substantial holder 9 Jun 2026 5:58PM $0.047 $0.053 risen by 12.77%

IMM Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2027F C2 -$2.90 -37.50% 0.00 0.00 0.00% 0.0%
2026F C2 -$4.60 8.80% 0.00 0.00 0.00% 0.0%
2025A -$61.43 -$4.20 18.50% 0.00 0.00 0.00% 0.0%

IMM Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2025 A 2026 F 2027 F 2025 A 2026 F 2027 F 2025 A 2026 F 2027 F
CSL Limited (CSL) $59,371M 0.1108 -0.1212 0.0167 13.2934 15.1275 14.8786 3.60% 2.94% 3.05%
Clinuvel Pharmaceuticals Limited (CUV) $519M 0.0287 0.0000 0.0000 14.3315 0.0000 0.0000 0.49% 0.00% 0.00%
Immutep Limited (IMM) $81M 0.1854 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Mesoblast Limited (MSB) $2,641M 0.0301 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Telix Pharmaceuticals Limited (TLX) $5,732M -1.3893 0.0000 -0.1305 0.0000 310.4779 357.0825 0.00% 0.00% 0.00%

IMM Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 0.54 0.00
Market 0.28 13.00 1.14 0.58
Sector 0.44 27.80 2.42 1.92

IMM Directors

Name Position Start Date
Mr Marc Voigt Chief Financial Officer, Chief Executive Officer, Executive Director 9 Jul 2014
Professor Frederic Triebel Executive Director 13 Sep 2022
Dr Russell J Howard Non-Executive Chairman, Non-Executive Director 8 May 2013
Mr Pete A Meyers Non-Executive Deputy Chairman, Non-Executive Director 12 Feb 2014
Ms Lis (Elisabeth) Boyce Non-Executive Director 11 Apr 2023

Immutep Limited (IMM) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
18 Sep 2024 VOIGT, Marc Buy Indirect Shares 29,500 $0.340 $10,030.000
16 Mar 2020 CHAMBERLAIN, Grant Buy Indirect Shares 360,623 $0.277 $99,755.740
6 Aug 2019 CHAMBERLAIN, Grant Issued Indirect Shares 401,635 $0.021 $8,434.335

See all changes in directors' interest & trades for Immutep Limited (IMM) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

IMM Management

Name Position
Christian Mueller Chief Development Officer
Florian Vogl Chief Medical Officer
Deanne Miller Chief Operating Officer,Company Secretary,General Counsel

IMM Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Immutep Limited (IMM). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
210,913,979 (14.50%) The Bank of New York Mellon Corporation
203,196,083 (13.91%) Regal Funds Management Pty Ltd
147,623,939 (10.16%) Insignia Financial Ltd

IMM Calendar of Events

Date Event
24 February 2027 Report (Interim)
26 October 2026 Report (Annual)
23 October 2026 Report (Annual)
28 August 2026 Report (Annual)
28 August 2026 Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.